<DOC>
	<DOCNO>NCT01554956</DOCNO>
	<brief_summary>Kedrion Human Plasminogen , sterile human plasma-derived plasminogen preparation topical ocular use evaluate indication treatment ligneous conjunctivitis . KB046 open-label , historically control clinical trial . At least 10 subject ligneous conjunctivitis , approximately 20 eye , treat assess . All subject receive investigational medicinal product ( IMP ) 12 48 week , possibility extend treatment ( Continuation segment )</brief_summary>
	<brief_title>Efficacy/Safety Human Plasminogen Eye Drop Ligneous Conjunctivitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Skin Diseases , Genetic</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Subjects diagnose ligneous conjunctivitis associate Type I plasminogen deficiency , confirmed central laboratory document preenrollment screening . The concomitant presence ligneous pseudomembranes different site constitute exclusion criterion . Subjects document historical record disease course available period least 6 month surround episode LC , even asymptomatic past newly diagnose subject , include limited age LC onset , diagnosis Plasminogen 1 deficiency , history pseudomembrane lesion , disease duration , past treatment LC , response treatment and/or surgery ( include regression recurrence ) , study entrance . If history 6 month surround LC episode available include . Subjects , legally authorize representative , case study participant &lt; 18 year age , informed nature study , agree provision , sign date informed consent approve investigational review board ( IRB ) ethic committee ( EC ) . Subjects available duration study include . The Investigator make sure plan subject leave area study site end study period . If come another center , must agree compliant protocol mandate study visit return followup . Subjects present ligneous conjunctivitis associate Type 1 plasminogen deficiency . Subjects history LC lesion Group 2 , Group 1 entry lesion could first include history . Subject present antibody plasminogen screen . Subjects condition , opinion Investigator , might interfere evaluation study objective , participation trial . Subjects unwilling give write informed consent assent participation . Subjects participate another clinical trial within 1 month study initiation , i.e . receive test drug within 30 day prior study . Females childbearing potential either pregnant use adequate method birth control Females breastfeeding . Subjects treat FFP Laboratory Grade Plasminogen undergo washout period least 15 day consider study . This information disseminate subject ahead Screening Visit occur follow signing Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Plasminogen Deficiency</keyword>
	<keyword>Ligneous Conjunctivitis</keyword>
	<keyword>Plasminogen</keyword>
	<keyword>Ligneous Conjunctivitis Plasminogen Deficient Patients</keyword>
</DOC>